Sino Biopharmaceutical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Sino Biopharmaceutical hat ein Gesamteigenkapital von CN¥42.1B und eine Gesamtverschuldung von CN¥9.5B, wodurch sich der Verschuldungsgrad auf 22.6% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CN¥66.7B bzw. CN¥24.6B. Sino Biopharmaceutical Das EBIT des Unternehmens beträgt CN¥5.9B, so dass der Zinsdeckungsgrad -22.2 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CN¥13.2B.

Wichtige Informationen

22.6%

Verhältnis von Schulden zu Eigenkapital

CN¥9.51b

Verschuldung

Zinsdeckungsgrad-22.2x
BargeldCN¥13.18b
EigenkapitalCN¥42.12b
GesamtverbindlichkeitenCN¥24.58b
GesamtvermögenCN¥66.70b

Jüngste Berichte zur Finanzlage

Recent updates

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Oct 02
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sep 02
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Jul 12
Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

May 21
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Apr 21
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Apr 03
What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20
Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Dec 18
Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Dec 02
Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

Nov 17
Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Aug 30
We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

May 26
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Apr 20
Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Feb 09
Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Nov 11
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Oct 24
Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Jul 08
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Apr 28
Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 1177Die kurzfristigen Aktiva des Unternehmens (CN¥25.2B) übersteigen seine kurzfristigen Passiva (CN¥21.9B).

Langfristige Verbindlichkeiten: 1177Die kurzfristigen Vermögenswerte des Unternehmens (CN¥25.2B) übersteigen seine langfristigen Verbindlichkeiten (CN¥2.6B).


Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 1177 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 1177Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 8.2% auf 22.6% gestiegen.

Schuldendeckung: 1177Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (68.1%).

Zinsdeckung: 1177 mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.


Bilanz


Entdecken Sie finanziell stabile Unternehmen